Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It holds an agreement with National Research Council of Canada Industrial Research Assistance Program to support research and development of liquid biopsy assay for the early detection and screening of lung cancer; and strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.